095700 Genexine

Genexine to Present at the 35th J.P. Morgan Healthcare Conference

Genexine Inc. (KOSDAQ: 095700), a clinical stage biotechnology company developing innovative biologics focused on immuno-oncology and metabolic/autoimmune diseases, today announced that Dr. H. Michael Keyoung, CEO and President of Genexine, will present at the J.P. Morgan 35th Annual Healthcare Conference Emerging Markets Track on January 11th at the Westin St. Francis Hotel, San Francisco. The J.P. Morgan Healthcare Conference is one of the healthcare industry’s biggest events of the year and it brings thousands of investors and executives from around the world to San Francisco.

Event: The 35th Annual J.P. Morgan Healthcare Conference Emerging Market Track

Date: January 11th, 2017 3pm (PST)

Location: Westin St. Francis Hotel, 335 Powell Street, San Francisco, CA

About Genexine

Genexine, Inc., listed on KOSDAQ (095700-KQ) since 2009, is a clinical stage biotherapeutics company focused on immuno-oncology and metabolic/autoimmune diseases. Genexine has robust pipelines in clinical and pre-clinical stages based on long-acting Fc fusion technology and therapeutic DNA vaccine technology. In the clinical stage, Genexine has GX-H9 (long-acting human growth hormone, hGH-hyFc) for both adult and pediatric GHD, currently in multinational phase II trials. GX-188E therapeutic DNA vaccine for HPV-associated diseases is in Phase II in Europe and Korea for Cervical Intraepithelial Neoplasia II/III and plans to enter into Phase 1b/2a trial in cervical cancer with GX-188E in combination Keytruda (anti- PD-1 therapy) of Merck (also known as MSD) 1H of 2017. Currently Genexine is running over 8 clinical trials from Phase I to Phase IIb in Europe and Asia. In addition to Merck (MSD) collaboration, Genexine has strategic partnerships with leading Asian companies such as Shanghai Fosun Pharma, Tasly Pharma, Kalbe Pharma (largest healthcare Indonesian company), and Korean big Pharma companies such as Green Cross and Yuhan. Founded in 1999, Genexine has over 150 employees and half of them are scientists with MSc or Ph.D. Genexine is located in Pangyo Techno Valley near Seoul, Korea with a branch office in New York.

EN
28/12/2016

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Genexine

Genexine Inc: 1 director

A director at Genexine Inc bought 5,000 shares at 7,710.000KRW and the significance rating of the trade was 68/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two years clearl...

Dave Nicoski ... (+2)
  • Dave Nicoski
  • Ross LaDuke

Vermilion Int'l Compass: Global Equity Strategy

Stay Defensive With Technology, Health Care, Staples Upside momentum continues to wane for global equities, a trend we mentioned in last week's Int'l Compass. In that report we highlighted early signs of lower highs forming in the major global indexes. Price action this week has indeed confirmed lower highs for now in the MSCI ACWI, ACWI ex-US, EAFE, and EM indexes. These lower highs increase the probability for breakdowns and a deeper pullback, but we do not want to get ahead of ourselves. Unt...

 PRESS RELEASE

Genexine Receives Approval to Initiate Phase Ib/II Trial of GX-188E, H...

SEONGNAM, South Korea--(BUSINESS WIRE)-- Genexine Inc. (KOSDAQ: 095700), a clinical stage biotechnology company developing innovative biologics focused on immuno-oncology and orphan diseases, announced that the Ministry of Food and Drug Safety (MFDS) in Korea has granted approval to initiate a Phase Ib/II trial of GX-188E, an HPV therapeutic DNA vaccine, in combination with KEYTRUDA® (pembrolizumab), an anti-PD-1 therapy marketed by Merck & Co., Inc., Kenilworth, NJ, USA (known as MSD outside the United States and Canada), for ...

 PRESS RELEASE

Genexine Releases Positive Interim Phase 2 Clinical Data from PGHD Tri...

ORLANDO, Fla.--(BUSINESS WIRE)-- Genexine Inc. (KOSDAQ: 095700) and Handok Inc. (KRX: 002390), co-developing next-generation, long-acting recombinant human growth hormone (rhGH), consisting Genexine’s proprietary hybrid Fc (hyFc) platform technology for pediatric and adult growth hormone deficiency (GHD) patients called GX-H9, today presented positive interim results from the ongoing phase 2 clinical trials of GX-H9 in pediatric growth hormone deficiency and full data from adult growth hormone deficiency (GHD) at the 99t...

 PRESS RELEASE

Genexine to Present at the 35th J.P. Morgan Healthcare Conference

SEONGNAM, South Korea--(BUSINESS WIRE)-- Genexine Inc. (KOSDAQ: 095700), a clinical stage biotechnology company developing innovative biologics focused on immuno-oncology and metabolic/autoimmune diseases, today announced that Dr. H. Michael Keyoung, CEO and President of Genexine, will present at the J.P. Morgan 35th Annual Healthcare Conference Emerging Markets Track on January 11th at the Westin St. Francis Hotel, San Francisco. The J.P. Morgan Healthcare Conference is one of the healthcare industry’s biggest events of the ye...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch